Current procedures for the treatment of metastatic pancreatic cancer

04/2017

MUDr. Petr Karásek

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

SUMMARY

Pancreatic cancer is a highly aggressive malignancy with poor treatment results at all stages. At the time of diagnosis, metastatic spread or locally advanced disease is present in most patients. Despite low efficacy, gemcitabine monotherapy has been used in palliative treatment of advanced disease for many years. In recent years therapeutic options have expanded significantly. In palliative treatment of the first line, FOLFIRINOX and nab-paclitaxel/ gemcitabine regimens have been introduced into clinical routine, which increased the overall survival by 4-5 months. Other possibilities prolongation of survival is the second line treatment with nanoliposomal irinotecan in combination with 5-fluorouracil and leucovorin in patients pretreated with gemcitabine regimen. Interesting results brings the studies aimed at influencing the extracellular matrix of tumor cells.

KEY WORDS

pancreatic cancer, chemotherapy, palliation